Primed for global coronavirus pandemic: Emerging research and clinical outcome

• Published in: European journal of medicinal chemistry 2021-01, Vol.209, p.112862-112862, Article 112862
• Main Authors: Ahamad, Shakir, Branch, Scotty, Harrelson, Shea, Hussain, Mohd Kamil, Saquib, Mohammad, Khan, Saeed
• Format: Article
• Language: English
• Subjects: Antiviral Agents - therapeutic use; Antiviral drugs; Clinical trials; Clinical Trials as Topic; COVID-19; COVID-19 - epidemiology; COVID-19 - prevention & control; COVID-19 - therapy; COVID-19 Drug Treatment; COVID-19 Vaccines - therapeutic use; Drug Repositioning; Drug repurposing; Humans; Monoclonal antibodies; Pandemics - prevention & control; Review; SARS-CoV-2; Small molecule drugs; Vaccines
• ISSN: 0223-5234; 1768-3254; 1768-3254
• DOI: 10.1016/j.ejmech.2020.112862

The global effort to combat and contain the coronavirus disease 2019 (COVID-19) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now proceeding on a war footing. The world was slow to react to the developing crisis, but once the contours of the impending calamity became evident, the different state and non-state actors have raced to put their act together. The COVID-19 pandemic has blatantly exposed the shortcomings of our healthcare system and the limitations of medical science, despite considerable advances in recent years. To effectively tackle the current pandemic, almost unprecedented in the modern age, there is an urgent need for a concerted, sustained, and coordinated effort towards the development of new diagnostics, therapeutic and vaccines, and the ramping up of the healthcare infrastructure, especially in the poorer underprivileged nations. Towards this end, researchers around the world are working tirelessly to develop new diagnostics, vaccines, and therapeutics. Efforts to develop a vaccine against COVID-19 are presently underway in several countries around the world, but a new vaccine is expected only by the end of the year-at the earliest. New drug development against COVID-19 and its approval may take even longer. Under such circumstances, drug repurposing has emerged as a realistic and effective strategy to counter the current menace, and several antiviral and antimalarial medicines are currently in different stages of clinical trials. Researchers are also experimenting with nutrients, vitamins, monoclonal antibodies, and convalescent plasma as immunity boosters against the SARS-CoV-2. This report presents a critical analysis of the global clinical trial landscape for COVID-19 with an emphasis on the therapeutic agents and vaccines currently being tested at pandemic speed. [Display omitted] •COVID-19, a highly infectious disease, has emerged as the gravest public health crisis since the Spanish flu outbreak of 1918-20.•To combat and control this pandemic, a massive global effort, unprecedented in history, is currently underway.•However, an effective vaccine against COVID-19 is not expected before December 2020.•A multitude of known drugs, especially anti-virals are also currently being repurposed as potential treatment for COVID-19.•This review discusses the various vaccines, drugs and other therapies, in clinical and preclinical trial, against COVID-19.